Atea Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
August 08, 2022 16:05 ET
|
Atea Pharmaceuticals, Inc.
Advancing Bemnifosbuvir to Late-Stage Development for COVID-19 Following Meetings with U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Emergency Task Force New Data...
Atea Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call on August 8, 2022
August 01, 2022 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and...
Atea Pharmaceuticals Participates in the William Blair Biotech Focus Conference
July 11, 2022 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief...
Atea Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference
June 01, 2022 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief...
First Orion Named as an Inc. Magazine’s Best Workplaces for 2022
May 10, 2022 13:09 ET
|
First Orion Corp.
NORTH LITTLE ROCK, Ark. , May 10, 2022 (GLOBE NEWSWIRE) -- First Orion has been named to Inc. magazine’s annual Best Workplaces list. Featured in the May/June 2022 issue, hitting newsstands on May...
Atea Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
May 10, 2022 06:30 ET
|
Atea Pharmaceuticals, Inc.
New clinical results from MORNINGSKY trial shows 71% reduction in hospitalization (secondary endpoint) in broad patient population with COVID-19 treated with bemnifosbuvir (AT-527) versus placebo...
Atea Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call on May 10, 2022
May 03, 2022 16:05 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and...
Atea Pharmaceuticals Reports Nonclinical Bemnifosbuvir (AT-527) Toxicology Data at Society of Toxicology 61st Annual Meeting
March 28, 2022 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, March 28, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today presented two posters highlighting nonclinical data...
With a Two-Year Revenue Growth of 803%, OJO Labs Ranks No. 16 on Inc. Magazine’s List of the Southwest Region’s Fastest-Growing Private Companies
March 15, 2022 16:03 ET
|
OJO Labs
AUSTIN, Texas, March 15, 2022 (GLOBE NEWSWIRE) -- Inc. magazine today revealed that OJO Labs is No. 16 on its third annual Inc. 5000 Regionals Southwest list, the most prestigious ranking of the...
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
February 28, 2022 16:05 ET
|
Atea Pharmaceuticals, Inc.
Developing bemnifosbuvir (AT-527), a nucleotide analog, as preferred backbone of combination therapy for COVID-19, progressing to Phase 2 combination clinical trial in 2H 2022 Initiating Phase 2...